Government must urgently offer clarity on Brexit to ensure UK border security, says FDA

February 14th 2018

Welcoming the report from the Home Affairs Select Committee on the delivery of Brexit by the Home Office, FDA National Officer Helen Kenny said:

“As we made clear in our evidence to the Committee, civil servants are committed to delivering the best possible Brexit outcomes for the Government, but to do so ministers must urgently clarify their intentions and deliver the consequent resources to turn these into a reality.

“The scale of the challenge on borders and immigration is laid bare in this report, as is the picture of a system already creaking under the weight of increased demands with fewer resources. The security of our borders and the running of an effective and efficient immigration system are critical to our national interest - these cannot be delivered on the cheap or materialise overnight.

“As the committee makes clear, the Government needs to urgently resolve the outstanding issues on customs, citizenship and immigration to give clearer direction to those tasked with designing and delivering our border security. Only then can a realistic assessment be made of the resources required and ministers be tested on whether they are prepared to fully fund any new system.”

Notes for editors
1. The FDA is the union for senior managers and professionals in public service, representing more than 18,000 members at grades HEO and above. Membership includes senior civil servants, Government policy advisors, prosecutors, diplomats, tax professionals, economists, solicitors and other professionals working across the Government and the NHS.

2. The FDA (formerly the First Division Association) should be referred to simply as "The FDA" and can be described as "the senior public servants' union".

3. The FDA's oral evidence to the Home Affairs Select Committee can be viewed here.

4. The FDA can be found on Twitter @FDA_union and at www.fda.org.uk. General Secretary Dave Penman tweets as @FDAGenSec.

5. For further information contact the FDA Communications team on 020 7401 5589.